CO2019012871A2 - Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida - Google Patents

Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida

Info

Publication number
CO2019012871A2
CO2019012871A2 CONC2019/0012871A CO2019012871A CO2019012871A2 CO 2019012871 A2 CO2019012871 A2 CO 2019012871A2 CO 2019012871 A CO2019012871 A CO 2019012871A CO 2019012871 A2 CO2019012871 A2 CO 2019012871A2
Authority
CO
Colombia
Prior art keywords
cell culture
culture methods
express proteins
heterogeneity
reduced heterogeneity
Prior art date
Application number
CONC2019/0012871A
Other languages
English (en)
Spanish (es)
Inventor
Yahia Bassem Ben
Laetitia Malphettes
Nadine Kochanowski
Gill Renner
Sandrine Durran
Andrew Jeffrey Yates
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59270991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019012871(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CO2019012871A2 publication Critical patent/CO2019012871A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CONC2019/0012871A 2017-05-31 2019-11-18 Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida CO2019012871A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1708655.4A GB201708655D0 (en) 2017-05-31 2017-05-31 Cell culture methods
PCT/EP2018/064102 WO2018219968A1 (en) 2017-05-31 2018-05-29 Cell culture methods

Publications (1)

Publication Number Publication Date
CO2019012871A2 true CO2019012871A2 (es) 2020-01-17

Family

ID=59270991

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0012871A CO2019012871A2 (es) 2017-05-31 2019-11-18 Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida

Country Status (21)

Country Link
US (3) US12077796B2 (enExample)
EP (2) EP3630946B1 (enExample)
JP (3) JP7460370B2 (enExample)
KR (3) KR20240096888A (enExample)
CN (2) CN119326882A (enExample)
AU (2) AU2018276376C1 (enExample)
BR (1) BR112019024390A2 (enExample)
CA (1) CA3065661A1 (enExample)
CL (1) CL2019003459A1 (enExample)
CO (1) CO2019012871A2 (enExample)
EA (1) EA201992828A1 (enExample)
ES (1) ES2978394T3 (enExample)
GB (1) GB201708655D0 (enExample)
HR (1) HRP20240585T1 (enExample)
HU (1) HUE066922T2 (enExample)
IL (2) IL317828A (enExample)
MX (1) MX2019014140A (enExample)
MY (1) MY193535A (enExample)
PL (1) PL3630946T3 (enExample)
RU (2) RU2758674C2 (enExample)
WO (1) WO2018219968A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
JP2023554489A (ja) * 2020-12-22 2023-12-27 ノバルティス アーゲー 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法
GB202105424D0 (en) 2021-04-16 2021-06-02 UCB Biopharma SRL Cell culture processes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
DK1623019T4 (en) 2003-05-15 2017-03-27 Wyeth Llc LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
US8030027B2 (en) * 2008-04-29 2011-10-04 St. Jude Children's Research Hospital Method for enhancing recombinant antibody production
US8252557B2 (en) 2008-10-28 2012-08-28 Chugai Seiyaku Kabushiki Kaisha Peptide-containing culture medium for culturing animal cell
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
US8986957B2 (en) * 2010-04-26 2015-03-24 Novartis Ag Cell culture medium
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
US9133493B2 (en) * 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
CA2868401C (en) 2012-03-26 2021-08-24 Sanofi Stable anti-cxcr5 igg4 antibody formulations
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
JP2016513478A (ja) * 2013-03-15 2016-05-16 ジェネンテック， インコーポレイテッド 細胞培養培地及び抗体を産生する方法
SG11201609980TA (en) 2014-06-18 2016-12-29 Medimmune Llc Cell culture methods and media comprising n-acetylcysteine
JP2018507355A (ja) 2014-12-29 2018-03-15 ウィロチャパイシット, ワンロプWIROJPAISIT, Wanlop 電圧を上昇させ、設置方法が改良された酸素効率の良いデバイスを備えたエンジン燃焼システム
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
US11220668B2 (en) * 2016-04-28 2022-01-11 Merck Patent Gmbh Method for reducing the trisulfide level in proteins
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN106222129A (zh) 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
WO2018018613A1 (zh) * 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods

Also Published As

Publication number Publication date
CN119326882A (zh) 2025-01-21
KR20250156183A (ko) 2025-10-31
AU2024259881B2 (en) 2025-02-13
HUE066922T2 (hu) 2024-09-28
MY193535A (en) 2022-10-18
IL270880A (en) 2020-01-30
MX2019014140A (es) 2020-02-07
KR20200012972A (ko) 2020-02-05
ES2978394T3 (es) 2024-09-11
JP2021185185A (ja) 2021-12-09
US20200239923A1 (en) 2020-07-30
IL270880B1 (en) 2025-01-01
JP2020521490A (ja) 2020-07-27
US20250051824A1 (en) 2025-02-13
EP4397682A3 (en) 2024-08-21
RU2019143742A (ru) 2021-06-30
US20250066832A1 (en) 2025-02-27
RU2019143742A3 (enExample) 2021-06-30
JP7406593B2 (ja) 2023-12-27
CN110741077A (zh) 2020-01-31
CL2019003459A1 (es) 2020-04-24
RU2758674C2 (ru) 2021-11-01
IL270880B2 (en) 2025-05-01
CN110741077B (zh) 2024-10-11
EA201992828A1 (ru) 2020-04-21
AU2018276376C1 (en) 2025-01-30
JP7560420B2 (ja) 2024-10-02
JP2022153421A (ja) 2022-10-12
GB201708655D0 (en) 2017-07-12
RU2021128024A (ru) 2021-12-08
JP7460370B2 (ja) 2024-04-02
EP3630946A1 (en) 2020-04-08
IL317828A (en) 2025-02-01
EP4397682A2 (en) 2024-07-10
CA3065661A1 (en) 2018-12-06
AU2018276376B2 (en) 2024-08-15
HRP20240585T1 (hr) 2024-07-19
EP3630946B1 (en) 2024-03-27
AU2018276376A1 (en) 2019-12-12
PL3630946T3 (pl) 2024-07-01
US12077796B2 (en) 2024-09-03
EP3630946C0 (en) 2024-03-27
AU2024259881A1 (en) 2024-11-28
KR20240096888A (ko) 2024-06-26
BR112019024390A2 (pt) 2020-07-14
WO2018219968A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
EA201890137A1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения
MX2019004328A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
CY1122612T1 (el) Μεθοδος
EA201890729A1 (ru) Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
MX384960B (es) Cultivo celular metabolicamente optimizado
EA201690529A1 (ru) Способы модификации клетки-хозяина
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
EA202191602A3 (ru) Не содержащая сыворотки среда для культивирования клеток
EA201692025A1 (ru) Доставка белков, осуществляемая на основе бактерий
MX2018013081A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
CO2019012871A2 (es) Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida
EA201791275A1 (ru) Способы получения ctp-модифицированных полипептидов длительного действия
EA202091349A1 (ru) Способы культивирования клеток
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
MX374934B (es) Marcador de seleccion novedoso para transfeccion celular y produccion de proteinas.
EA201591832A1 (ru) Коэкспрессия фактора viii и фактора фон виллебранда
MX382786B (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.
MX2016013955A (es) Drimenol-sintasas y metodo de produccion de drimenol.
AR112851A1 (es) Procedimiento para la obtención de una glicoproteína con un mayor porcentaje de glicanos afucosilados
AR094875A1 (es) Formulaciones y procedimientos para la producción de proteína recombinante aumentada
MX2020002382A (es) Métodos y composiciones para mejorar la expresión de proteínas recombinantes.
MX2018013683A (es) Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.